Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy

Completed · Phase 1

Conditions studied: Prostate Cancer

In brief

RATIONALE: Diindolylmethane may slow the growth of prostate cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of diindolylmethane in treating patients with nonmetastatic prostate cancer that has not responded to previous hormone therapy.

Key facts

Study ID

NCT00305747

Run by

Barbara Ann Karmanos Cancer Institute

People needed

12

Starts

2005-08-01

Expected to finish

2010-09-01

Last updated by the study team

2014-01-15

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
• Weisberg Cancer Treatment Center — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.